US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Zura Bio

1.37

+0.0000

Volume:86.81K

Turnover:120.24K

Market Cap:93.67M

PE:-2.27

High:1.45

Open:1.37

Low:1.35

Close:1.37

Loading ...

Overview Company News Filings

Cautious Hold Rating on Zura Bio Due to Efficacy Concerns and Competitive Risks

Zura Bio Begins Phase 2 Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis

MT Newswires Live

Zura Bio Initiates Global Phase 2 TibuSURE Study

Zura Bio launches global Phase 2 TibuSURE study evaluating tibulizumab

Zura Bio Launches Global Phase 2 Tibusure Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis

THOMSON REUTERS

Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis

Positive Buy Rating for Zura Bio Driven by Promising Tibulizumab Data and IL-17/BAFF Hypotheses Support

Zura Bio Ltd : Leerink Partners Cuts Target Price to $12 From $15

THOMSON REUTERS

Zura Bio to Present at Healthcare Conference

Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference

Zura Bio Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Cautious Hold Rating for Zura Bio Amid Efficacy Concerns and Licensing Challenges

Zura Bio Announces Phase 2 Tibulizumab Study

Zura Bio submits protocol to FDA for Phase 2 study of Tibulizumab

Zura Bio Ltd - Trial Is Expected to Initiate in Q4 2024

THOMSON REUTERS

Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults With Systemic Sclerosis

THOMSON REUTERS

Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis

Zura Bio Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Zura Bio price target raised to $12 from $11 at Chardan

Calendar of U.S. Earnings Expected in the Week Ahead

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ZURA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ZURA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZURA\",,,,,undefined,":{"symbol":"ZURA","market":"US","secType":"STK","nameCN":"Zura Bio","latestPrice":1.37,"timestamp":1745332108080,"preClose":1.37,"halted":0,"volume":86814,"delay":0,"floatShares":46618183,"shares":68374998,"eps":-0.604576,"marketStatus":"Trading","change":0,"latestTime":"04-22 10:28:37 EDT","open":1.37,"high":1.4498,"low":1.35,"amount":120238.16264460002,"amplitude":0.072847,"askPrice":1.4,"askSize":205,"bidPrice":1.37,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.604576,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745352000000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":1.37,"postHourTrading":{"tag":"盘后","latestPrice":1.38,"preClose":1.37,"latestTime":"18:06 EDT","volume":2909,"amount":4009.62,"timestamp":1745273203807},"volumeRatio":1.95655,"impliedVol":0.7265,"impliedVolPercentile":0.314},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZURA\",,,,,undefined,":{"symbol":"ZURA","floatShares":46618183,"roa":"-24.60%","roe":"-43.75%","lyrEps":-0.604576,"volumeRatio":1.95655,"shares":68374998,"dividePrice":0,"high":1.4498,"amplitude":0.072847,"preClose":1.37,"low":1.35,"week52Low":0.97,"pbRate":"0.64","week52High":6.35,"institutionHeld":0,"latestPrice":1.37,"committee":-0.344262,"eps":-0.604576,"divideRate":0,"volume":86814,"delay":0,"ttmEps":-0.604576,"open":1.37,"prevYearClose":2.5,"prevWeekClose":1.23,"prevMonthClose":1.29,"prevQuarterClose":1.29,"fiveDayClose":1.12,"twentyDayClose":1.35,"sixtyDayClose":1.72},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ZURA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2493161702","title":"Cautious Hold Rating on Zura Bio Due to Efficacy Concerns and Competitive Risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2493161702","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493161702?lang=en_us&edition=fundamental","pubTime":"2024-12-24 19:15","pubTimestamp":1735038937,"startTime":"0","endTime":"0","summary":"Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Hold rating on Zura Bio (ZURA – Research Report). The associated price target rema...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cautious-hold-rating-on-zura-bio-due-to-efficacy-concerns-and-competitive-risks?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cautious-hold-rating-on-zura-bio-due-to-efficacy-concerns-and-competitive-risks?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZURA"],"gpt_icon":0},{"id":"2493661027","title":"Zura Bio Begins Phase 2 Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2493661027","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493661027?lang=en_us&edition=fundamental","pubTime":"2024-12-23 22:51","pubTimestamp":1734965476,"startTime":"0","endTime":"0","summary":"Zura Bio  said Monday that it has begun a phase 2 study evaluating tibulizumab as a treatment for adult patients with systemic sclerosis.The immunology company said the study includes a 24-week efficacy period and a 28-week open-label extension. It also said the primary endpoint of the trial is the modified Rodnan Skin Score.Shares of Zura Bio were down 1.8% in recent trading.Price: 2.24, Change: -0.04, Percent Change: -1.75","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ZURA","BK4139"],"gpt_icon":0},{"id":"2493708759","title":"Zura Bio Initiates Global Phase 2 TibuSURE Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2493708759","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493708759?lang=en_us&edition=fundamental","pubTime":"2024-12-23 20:18","pubTimestamp":1734956313,"startTime":"0","endTime":"0","summary":"An update from Zura Bio ( ($ZURA) ) is now available. Zura Bio has announced the launch of its global Phase 2 TibuSURE study, which will evaluate t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/zura-bio-initiates-global-phase-2-tibusure-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/zura-bio-initiates-global-phase-2-tibusure-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ZURA"],"gpt_icon":0},{"id":"2493561077","title":"Zura Bio launches global Phase 2 TibuSURE study evaluating tibulizumab","url":"https://stock-news.laohu8.com/highlight/detail?id=2493561077","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493561077?lang=en_us&edition=fundamental","pubTime":"2024-12-23 19:55","pubTimestamp":1734954926,"startTime":"0","endTime":"0","summary":"Zura Bio (ZURA) announced the launch of TibuSURE, a Phase 2 global study evaluating tibulizumab for the treatment of systemic sclerosis in adults. ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zura-bio-launches-global-phase-2-tibusure-study-evaluating-tibulizumab?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zura-bio-launches-global-phase-2-tibusure-study-evaluating-tibulizumab?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ZURA"],"gpt_icon":0},{"id":"2493755118","title":"Zura Bio Launches Global Phase 2 Tibusure Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2493755118","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493755118?lang=en_us&edition=fundamental","pubTime":"2024-12-23 19:44","pubTimestamp":1734954240,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241223:nTUAB5YNG4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZURA","BK4139"],"gpt_icon":0},{"id":"2493759132","title":"Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2493759132","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493759132?lang=en_us&edition=fundamental","pubTime":"2024-12-23 19:30","pubTimestamp":1734953400,"startTime":"0","endTime":"0","summary":"Phase 2 TibuSURE study will evaluate tibulizumab in adults with systemic sclerosis . . \"Single-pathway inhibition has demonstrated modest effects in rheumatic diseases like SSc. This is why we believe tibulizumab's dual-pathway approach holds the potential to be best-in-class, aiming to provide deeper efficacy and greater benefits for patients affected by this life-threatening autoimmune disease,\" said Kiran Nistala, MBBS, PhD, Chief Medical Officer and Head of Development at Zura Bio. \"The initiation of the TibuSURE study marks a significant milestone in addressing certain urgent, unmet needs of this patient population and advancing our mission to improve the lives of those affected by autoimmune and inflammatory conditions.\". \"Systemic sclerosis is a heterogeneous and complex autoimmune disease characterized by both inflammatory and fibrotic processes, for which effective therapies remain limited,\" said Christopher Denton, PhD, FRCP, FMedSci, Professor of Experimental Rheumatology at","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/cuJkwiBQSzff0Wdx9vP_7w--~B/aD01Nzk7dz0xOTIwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/389cb0d2cff9beff474a45e447b26640","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/cuJkwiBQSzff0Wdx9vP_7w--~B/aD01Nzk7dz0xOTIwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/389cb0d2cff9beff474a45e447b26640"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zura-bio-launches-global-phase-113000827.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ZURA","BK4139","FVC","ZURAW"],"gpt_icon":0},{"id":"2493442295","title":"Positive Buy Rating for Zura Bio Driven by Promising Tibulizumab Data and IL-17/BAFF Hypotheses Support","url":"https://stock-news.laohu8.com/highlight/detail?id=2493442295","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493442295?lang=en_us&edition=fundamental","pubTime":"2024-12-21 01:58","pubTimestamp":1734717518,"startTime":"0","endTime":"0","summary":"In a report released on December 17, Faisal Khurshid from Leerink Partners reiterated a Buy rating on Zura Bio (ZURA – Research Report), with a pri...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/positive-buy-rating-for-zura-bio-driven-by-promising-tibulizumab-data-and-il-17-baff-hypotheses-support?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/positive-buy-rating-for-zura-bio-driven-by-promising-tibulizumab-data-and-il-17-baff-hypotheses-support?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZURA"],"gpt_icon":0},{"id":"2490439854","title":"Zura Bio Ltd : Leerink Partners Cuts Target Price to $12 From $15","url":"https://stock-news.laohu8.com/highlight/detail?id=2490439854","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490439854?lang=en_us&edition=fundamental","pubTime":"2024-12-11 21:23","pubTimestamp":1733923439,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nFWN3NC1H2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZURA","BK4139"],"gpt_icon":0},{"id":"2486208516","title":"Zura Bio to Present at Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2486208516","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486208516?lang=en_us&edition=fundamental","pubTime":"2024-11-25 20:24","pubTimestamp":1732537445,"startTime":"0","endTime":"0","summary":"An announcement from Zura Bio ( ($ZURA) ) is now available. Zura Bio Limited, a clinical-stage immunology company, is set to present at the Piper S...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/zura-bio-to-present-at-healthcare-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/zura-bio-to-present-at-healthcare-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZURA","HCSG","BK4139","BK4137"],"gpt_icon":0},{"id":"2486700957","title":"Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2486700957","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486700957?lang=en_us&edition=fundamental","pubTime":"2024-11-25 19:30","pubTimestamp":1732534200,"startTime":"0","endTime":"0","summary":"HENDERSON, Nev., November 25, 2024----Zura Bio Limited  , a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 9:00 a.m. ET, and will host investor meetings in New York, NY.A live webcast and a replay of the presentation will be available on the \"News & Events\" page within the Investors section of the Zura Bio website. The presentation will be archived on the website for at least 30 days following the events.Zura Bio is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. Currently, Zura Bio is developing three assets which have completed Phase 1/1b studies. The company is developing a portfolio of therapeutic indications for tibulizumab , crebankitug","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/dIgHSo5w17dbAPLmq0UlIQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/0cfd9227d2e8976e4e93e96ce3d0cf83","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/dIgHSo5w17dbAPLmq0UlIQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/0cfd9227d2e8976e4e93e96ce3d0cf83"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zura-bio-present-piper-sandler-113000648.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ZURA","ZURAW","BK4137","BK4139","HCSG"],"gpt_icon":0},{"id":"2484238976","title":"Zura Bio Price Target Maintained With a $5.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2484238976","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484238976?lang=en_us&edition=fundamental","pubTime":"2024-11-18 19:27","pubTimestamp":1731929220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZURA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 18, 2024 06:27 ET (11:27 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZURA"],"gpt_icon":0},{"id":"2484883625","title":"Cautious Hold Rating for Zura Bio Amid Efficacy Concerns and Licensing Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2484883625","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484883625?lang=en_us&edition=fundamental","pubTime":"2024-11-18 19:25","pubTimestamp":1731929156,"startTime":"0","endTime":"0","summary":"Zura Bio (ZURA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mitchell Kapoor from H.C. W...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cautious-hold-rating-for-zura-bio-amid-efficacy-concerns-and-licensing-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cautious-hold-rating-for-zura-bio-amid-efficacy-concerns-and-licensing-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZURA"],"gpt_icon":0},{"id":"2483356250","title":"Zura Bio Announces Phase 2 Tibulizumab Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2483356250","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483356250?lang=en_us&edition=fundamental","pubTime":"2024-11-15 06:17","pubTimestamp":1731622669,"startTime":"0","endTime":"0","summary":"Zura Bio ( ($ZURA) ) has provided an update. Zura Bio Limited has submitted a protocol to the FDA for a Phase 2 study of tibulizumab, an investigat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/zura-bio-announces-phase-2-tibulizumab-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/zura-bio-announces-phase-2-tibulizumab-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZURA","BK4139"],"gpt_icon":0},{"id":"2483580563","title":"Zura Bio submits protocol to FDA for Phase 2 study of Tibulizumab","url":"https://stock-news.laohu8.com/highlight/detail?id=2483580563","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483580563?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:36","pubTimestamp":1731620208,"startTime":"0","endTime":"0","summary":"Zura Bio (ZURA) “announced the submission of a protocol to its open Investigational New Drug application with the U.S. Food and Drug Administration...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zura-bio-submits-protocol-to-fda-for-phase-2-study-of-tibulizumab?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zura-bio-submits-protocol-to-fda-for-phase-2-study-of-tibulizumab?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZURA","BK4139"],"gpt_icon":0},{"id":"2483358399","title":"Zura Bio Ltd - Trial Is Expected to Initiate in Q4 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483358399","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483358399?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:30","pubTimestamp":1731619805,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nFWN3ML1PO:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZURA","BK4139"],"gpt_icon":0},{"id":"2483335836","title":"Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults With Systemic Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2483335836","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483335836?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:30","pubTimestamp":1731619805,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nFWN3ML1PO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZURA"],"gpt_icon":0},{"id":"2483358306","title":"Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2483358306","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483358306?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:30","pubTimestamp":1731619800,"startTime":"0","endTime":"0","summary":"HENDERSON, Nev., November 14, 2024----Zura Bio Limited  , a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the submission of a protocol to its open Investigational New Drug  application with the U.S. Food and Drug Administration  for a Phase 2 study evaluating tibulizumab, a humanized tetravalent bispecific dual antagonist antibody designed to neutralize both IL-17A and BAFF, for the treatment of systemic sclerosis  in adults.\"Systemic sclerosis presents significant unmet needs, as current treatments largely target only its interstitial lung disease  component,\" said Robert Lisicki, CEO of Zura Bio. \"Tibulizumab, with dual IL-17A and BAFF inhibition, offers a potential first-in-class approach addressing both immune dysregulation and fibrosis—key drivers of the disease. This study protocol reflects our commitment to advancing therapies that could potentially bring meaningful improvements f","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/N1a44qhMZDZzjCEAMMiChw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/08295d8b5aa22ba2d5ea61b826cc54ed","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/N1a44qhMZDZzjCEAMMiChw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/08295d8b5aa22ba2d5ea61b826cc54ed"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zura-bio-announces-submission-protocol-213000907.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ZURAW","BK4139","ZURA"],"gpt_icon":0},{"id":"2482733456","title":"Zura Bio Price Target Maintained With a $5.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2482733456","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482733456?lang=en_us&edition=fundamental","pubTime":"2024-11-11 22:55","pubTimestamp":1731336900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZURA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 11, 2024 09:55 ET (14:55 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZURA"],"gpt_icon":0},{"id":"2482841423","title":"Zura Bio price target raised to $12 from $11 at Chardan","url":"https://stock-news.laohu8.com/highlight/detail?id=2482841423","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482841423?lang=en_us&edition=fundamental","pubTime":"2024-11-09 21:25","pubTimestamp":1731158715,"startTime":"0","endTime":"0","summary":"Chardan analyst Daniil Gataulin raised the firm’s price target on Zura Bio (ZURA) to $12 from $11 and keeps a Buy rating on the shares following th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zura-bio-price-target-raised-to-12-from-11-at-chardan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zura-bio-price-target-raised-to-12-from-11-at-chardan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZURA"],"gpt_icon":0},{"id":"2481220901","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2481220901","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481220901?lang=en_us&edition=fundamental","pubTime":"2024-11-08 19:00","pubTimestamp":1731063600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.Amer. Axle & Mnfg                                3Q      (.05)  8:00 AM","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HLLY","ANIP","GSL","GCMG","BLMN","WMS","OCS","MSGE","ZETA","SBS","ALT","FLR","BNTC","AHR","AVTE","BAX","ZURA","ATAI","SGMT","VINC","LAZR","XAIR","ABOS","ATOS","INTS","PARA","RBA","XERS","AMRX","AMTX","CLMT","GATO","ACLX","GTN","MASS","HUMA","VRDN","APGE","AGO","COCP","ATSG","AIRS","KT","NRXP","TSVT","FBRX","PAA","NPWR","TSBX","PAGP"],"gpt_icon":1}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":49,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ZURA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-25","symbol":"ZURA","fiscalQuarterEnding":"2024/12","expectedEps":-0.17,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742875200000,"reportTimeType":"pre","actualEps":-0.08},{"market":"US","date":"2024-11-07","symbol":"ZURA","fiscalQuarterEnding":"2024/09","expectedEps":-0.14,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"pre","actualEps":-0.26},{"market":"US","date":"2024-08-13","symbol":"ZURA","fiscalQuarterEnding":"2024/06","expectedEps":-0.13,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"pre","actualEps":-0.17},{"market":"US","date":"2024-05-09","symbol":"ZURA","fiscalQuarterEnding":"2024/03","expectedEps":-0.23,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"pre","actualEps":-0.02},{"date":"2024-03-28","symbol":"ZURA","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711612800000,"name":null,"time":"Pre-Market","dateTimestamp":1711598400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ZURA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ZURA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.375,"hold":0.125,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.375,"analysts":8,"updateTime":1730952000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ZURA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ZURA","date":"2025-04-21","current":-1.604894,"percent":0.92016,"low":-19.645373,"twenty":-7.43626,"median":-3.851042,"eighty":-2.098794,"high":128.323671,"avg":-0.805025,"sd":20.622509,"marketCap":84101247},"quantilePoints":[{"date":"2023-03-17","current":6.722013,"twenty":3.077283,"median":4.444057,"eighty":5.810831,"marketCap":55244013},{"date":"2023-03-24","current":95.732999,"twenty":10.089418,"median":26.552728,"eighty":97.24286,"marketCap":786769586},{"date":"2023-03-31","current":115.825116,"twenty":24.157776,"median":96.676662,"eighty":121.414532,"marketCap":411078048},{"date":"2023-04-06","current":88.654345,"twenty":26.552728,"median":98.493858,"eighty":115.825116,"marketCap":314645530},{"date":"2023-04-14","current":87.334622,"twenty":54.797542,"median":97.620325,"eighty":115.825116,"marketCap":309961665},{"date":"2023-04-21","current":-9.744092,"twenty":23.559038,"median":92.924037,"eighty":110.2357,"marketCap":273592829},{"date":"2023-04-28","current":-7.850225,"twenty":-7.693221,"median":87.334622,"eighty":108.0657,"marketCap":220417184},{"date":"2023-05-05","current":-5.625705,"twenty":-7.58528,"median":65.049697,"eighty":103.1713,"marketCap":157957503},{"date":"2023-05-12","current":-8.54785,"twenty":-7.58528,"median":23.559038,"eighty":100.454223,"marketCap":240004959},{"date":"2023-05-19","current":-6.028363,"twenty":-7.236336,"median":-1.370145,"eighty":99.367392,"marketCap":169263255},{"date":"2023-05-26","current":-6.110447,"twenty":-6.948723,"median":-5.106395,"eighty":97.620325,"marketCap":171568003},{"date":"2023-06-02","current":-7.079022,"twenty":-6.974783,"median":-5.279277,"eighty":96.110464,"marketCap":198763468},{"date":"2023-06-09","current":-7.871872,"twenty":-7.497414,"median":-5.756178,"eighty":93.610039,"marketCap":221024977},{"date":"2023-06-16","current":-12.462533,"twenty":-7.876403,"median":-5.936326,"eighty":92.830881,"marketCap":349920722},{"date":"2023-06-23","current":-18.356145,"twenty":-8.029209,"median":-6.09739,"eighty":90.300117,"marketCap":515400472},{"date":"2023-06-30","current":-12.800188,"twenty":-8.465056,"median":-6.110447,"eighty":88.126456,"marketCap":359401332},{"date":"2023-07-07","current":-10.897043,"twenty":-9.736242,"median":-6.32748,"eighty":86.946468,"marketCap":305965163},{"date":"2023-07-14","current":-10.375213,"twenty":-10.301543,"median":-6.449998,"eighty":83.375453,"marketCap":291313310},{"date":"2023-07-21","current":-10.144993,"twenty":-10.16955,"median":-6.948723,"eighty":71.20099,"marketCap":284849257},{"date":"2023-07-28","current":-10.083602,"twenty":-10.362935,"median":-7.293596,"eighty":49.148579,"marketCap":283125510},{"date":"2023-08-04","current":-9.776643,"twenty":-10.464231,"median":-7.58528,"eighty":25.95399,"marketCap":274506773},{"date":"2023-08-11","current":-10.449013,"twenty":-10.439697,"median":-7.861048,"eighty":20.191633,"marketCap":293385452},{"date":"2023-08-18","current":-10.480065,"twenty":-10.545755,"median":-7.939831,"eighty":5.810831,"marketCap":294257326},{"date":"2023-08-25","current":-10.480065,"twenty":-10.559049,"median":-8.143707,"eighty":0.751603,"marketCap":294257326},{"date":"2023-09-01","current":-10.681903,"twenty":-10.607717,"median":-8.54785,"eighty":-4.921342,"marketCap":299924504},{"date":"2023-09-08","current":-4.570525,"twenty":-10.559388,"median":-8.166359,"eighty":-4.757501,"marketCap":287718274},{"date":"2023-09-15","current":-4.764426,"twenty":-10.559388,"median":-7.953905,"eighty":-4.66055,"marketCap":299924504},{"date":"2023-09-22","current":-4.258898,"twenty":-10.557695,"median":-7.871872,"eighty":-4.251973,"marketCap":268101119},{"date":"2023-09-29","current":-4.473574,"twenty":-10.542169,"median":-7.639251,"eighty":-4.258898,"marketCap":281615159},{"date":"2023-10-06","current":-4.757501,"twenty":-10.497996,"median":-7.350856,"eighty":-4.283136,"marketCap":299488567},{"date":"2023-10-13","current":-4.383549,"twenty":-10.495591,"median":-7.013872,"eighty":-4.383549,"marketCap":275947981},{"date":"2023-10-20","current":-3.573319,"twenty":-10.495591,"median":-6.455254,"eighty":-4.196573,"marketCap":224943378},{"date":"2023-10-27","current":-3.573319,"twenty":-10.490414,"median":-6.444741,"eighty":-4.161948,"marketCap":224943378},{"date":"2023-11-03","current":-3.414044,"twenty":-10.481615,"median":-6.238867,"eighty":-3.923726,"marketCap":214916832},{"date":"2023-11-10","current":-2.956991,"twenty":-10.480065,"median":-6.108894,"eighty":-3.419584,"marketCap":186145005},{"date":"2023-11-17","current":-2.648491,"twenty":-10.467644,"median":-5.982344,"eighty":-3.254768,"marketCap":185709068},{"date":"2023-11-24","current":-2.791485,"twenty":-10.449013,"median":-5.807949,"eighty":-3.105187,"marketCap":195735614},{"date":"2023-12-01","current":-3.015301,"twenty":-10.439697,"median":-5.625705,"eighty":-2.958376,"marketCap":211429338},{"date":"2023-12-08","current":-2.486846,"twenty":-10.40006,"median":-5.130482,"eighty":-2.892202,"marketCap":174374712},{"date":"2023-12-15","current":-2.611189,"twenty":-10.387491,"median":-4.906391,"eighty":-2.779051,"marketCap":183093447},{"date":"2023-12-22","current":-3.183163,"twenty":-10.362935,"median":-4.840601,"eighty":-2.781538,"marketCap":223199631},{"date":"2023-12-29","current":-2.984215,"twenty":-10.326099,"median":-4.826751,"eighty":-2.788998,"marketCap":209249654},{"date":"2024-01-05","current":-2.517932,"twenty":-10.262321,"median":-4.816363,"eighty":-2.775321,"marketCap":176554395},{"date":"2024-01-12","current":-2.443326,"twenty":-10.181318,"median":-4.764426,"eighty":-2.706932,"marketCap":171323154},{"date":"2024-01-19","current":-2.505498,"twenty":-10.172619,"median":-4.757501,"eighty":-2.649734,"marketCap":175682522},{"date":"2024-01-26","current":-2.238162,"twenty":-10.157271,"median":-4.695176,"eighty":-2.617406,"marketCap":156937240},{"date":"2024-02-02","current":-1.933523,"twenty":-10.132715,"median":-4.639775,"eighty":-2.529123,"marketCap":135576338},{"date":"2024-02-09","current":-2.437109,"twenty":-10.071324,"median":-4.573987,"eighty":-2.500524,"marketCap":170887217},{"date":"2024-02-16","current":-2.493063,"twenty":-10.01914,"median":-4.570525,"eighty":-2.486846,"marketCap":174810648},{"date":"2024-02-23","current":-2.275464,"twenty":-10.006862,"median":-4.432024,"eighty":-2.486846,"marketCap":159552861},{"date":"2024-03-01","current":-2.287899,"twenty":-9.776643,"median":-4.271017,"eighty":-2.449544,"marketCap":160424735},{"date":"2024-03-08","current":-2.001911,"twenty":-9.745947,"median":-4.196573,"eighty":-2.424675,"marketCap":140371643},{"date":"2024-03-15","current":-1.970826,"twenty":-9.744092,"median":-4.127323,"eighty":-2.35007,"marketCap":138191959},{"date":"2024-03-22","current":-1.796746,"twenty":-9.744092,"median":-3.981897,"eighty":-2.287899,"marketCap":125985729},{"date":"2024-03-28","current":-1.675569,"twenty":-9.733298,"median":-3.573319,"eighty":-2.275464,"marketCap":101137332},{"date":"2024-04-05","current":-2.094461,"twenty":-9.709993,"median":-3.420969,"eighty":-2.199615,"marketCap":126421666},{"date":"2024-04-12","current":-2.072794,"twenty":-9.700891,"median":-3.379418,"eighty":-2.090128,"marketCap":125113855},{"date":"2024-04-19","current":-2.665021,"twenty":-9.687625,"median":-3.254768,"eighty":-2.111795,"marketCap":160860671},{"date":"2024-04-26","current":-3.737907,"twenty":-9.574049,"median":-3.270203,"eighty":-2.116128,"marketCap":225620043},{"date":"2024-05-03","current":-4.502009,"twenty":-9.49731,"median":-3.407119,"eighty":-2.159044,"marketCap":271741268},{"date":"2024-05-10","current":-4.89959,"twenty":-8.765356,"median":-3.41781,"eighty":-2.190413,"marketCap":286699503},{"date":"2024-05-17","current":-6.390769,"twenty":-8.555367,"median":-3.573319,"eighty":-2.204775,"marketCap":373955874},{"date":"2024-05-24","current":-6.007323,"twenty":-8.382261,"median":-3.737907,"eighty":-2.231945,"marketCap":351518521},{"date":"2024-05-31","current":-5.719739,"twenty":-8.236161,"median":-3.981897,"eighty":-2.251609,"marketCap":334690507},{"date":"2024-06-07","current":-4.462887,"twenty":-8.139176,"median":-4.127323,"eighty":-2.264907,"marketCap":261145852},{"date":"2024-06-14","current":-3.972928,"twenty":-8.059824,"median":-4.089234,"eighty":-2.268376,"marketCap":232475901},{"date":"2024-06-21","current":-3.685344,"twenty":-7.962349,"median":-4.015533,"eighty":-2.27049,"marketCap":215647887},{"date":"2024-06-28","current":-3.589482,"twenty":-7.95109,"median":-3.999556,"eighty":-2.272977,"marketCap":210038549},{"date":"2024-07-05","current":-3.7386,"twenty":-7.921709,"median":-3.982738,"eighty":-2.275464,"marketCap":218764186},{"date":"2024-07-12","current":-4.303144,"twenty":-7.885464,"median":-3.972928,"eighty":-2.277951,"marketCap":251798489},{"date":"2024-07-15","current":-4.041687,"twenty":-7.880933,"median":-3.977412,"eighty":-2.279194,"marketCap":236499340},{"date":"2024-08-02","current":-4.096158,"twenty":-7.876403,"median":-3.981897,"eighty":-2.280438,"marketCap":239686663},{"date":"2024-08-09","current":-3.856489,"twenty":-7.854554,"median":-3.977412,"eighty":-2.286655,"marketCap":225662443},{"date":"2024-08-16","current":-6.331005,"twenty":-7.724622,"median":-3.981897,"eighty":-2.287899,"marketCap":220439248},{"date":"2024-08-23","current":-6.444331,"twenty":-7.606868,"median":-3.996293,"eighty":-2.297846,"marketCap":224385162},{"date":"2024-08-30","current":-7.587973,"twenty":-7.667112,"median":-4.015533,"eighty":-2.31028,"marketCap":264205627},{"date":"2024-09-06","current":-6.9051,"twenty":-7.617018,"median":-4.085772,"eighty":-2.327688,"marketCap":240428669},{"date":"2024-09-13","current":-6.593729,"twenty":-7.586357,"median":-4.112499,"eighty":-2.345096,"marketCap":229587058},{"date":"2024-09-20","current":-7.875842,"twenty":-7.586357,"median":-4.161948,"eighty":-2.364991,"marketCap":274228948},{"date":"2024-09-27","current":-7.271417,"twenty":-7.617018,"median":-4.255435,"eighty":-2.378668,"marketCap":253183470},{"date":"2024-10-04","current":-7.601103,"twenty":-7.593225,"median":-4.283136,"eighty":-2.384885,"marketCap":264662822},{"date":"2024-10-11","current":-7.069942,"twenty":-7.673424,"median":-4.343346,"eighty":-2.389293,"marketCap":246168311},{"date":"2024-10-18","current":-8.956481,"twenty":-7.692898,"median":-4.432024,"eighty":-2.411035,"marketCap":311855710},{"date":"2024-10-25","current":-8.42532,"twenty":-7.821637,"median":-4.487792,"eighty":-2.425882,"marketCap":293361200},{"date":"2024-10-31","current":-8.480267,"twenty":-7.887052,"median":-4.562081,"eighty":-2.430855,"marketCap":295274425},{"date":"2024-11-08","current":-6.033112,"twenty":-7.921709,"median":-4.570525,"eighty":-2.439596,"marketCap":285070557},{"date":"2024-11-15","current":-4.97464,"twenty":-7.887052,"median":-4.636313,"eighty":-2.443326,"marketCap":235056708},{"date":"2024-11-22","current":-4.048804,"twenty":-7.875842,"median":-4.570525,"eighty":-2.445813,"marketCap":191310042},{"date":"2024-11-29","current":-4.214625,"twenty":-7.875048,"median":-4.570525,"eighty":-2.452031,"marketCap":199145266},{"date":"2024-12-06","current":-3.869164,"twenty":-7.867543,"median":-4.487792,"eighty":-2.463221,"marketCap":182821884},{"date":"2024-12-13","current":-3.040058,"twenty":-7.840696,"median":-4.435721,"eighty":-2.469438,"marketCap":143645766},{"date":"2024-12-20","current":-3.233516,"twenty":-7.788703,"median":-4.396313,"eighty":-2.476899,"marketCap":152786860},{"date":"2024-12-27","current":-3.689525,"twenty":-7.733197,"median":-4.359719,"eighty":-2.486846,"marketCap":174333725},{"date":"2025-01-03","current":-3.247334,"twenty":-7.715439,"median":-4.294156,"eighty":-2.486846,"marketCap":153439795},{"date":"2025-01-10","current":-2.991693,"twenty":-7.700332,"median":-4.27715,"eighty":-2.486846,"marketCap":141360492},{"date":"2025-01-17","current":-2.48732,"twenty":-7.692898,"median":-4.251973,"eighty":-2.486846,"marketCap":117528354},{"date":"2025-01-24","current":-2.376772,"twenty":-7.679844,"median":-4.214625,"eighty":-2.479386,"marketCap":112304871},{"date":"2025-01-31","current":-2.432046,"twenty":-7.644119,"median":-4.17926,"eighty":-2.464465,"marketCap":114916612},{"date":"2025-02-07","current":-2.445865,"twenty":-7.612093,"median":-4.159352,"eighty":-2.447337,"marketCap":115569548},{"date":"2025-02-14","current":-2.072767,"twenty":-7.595851,"median":-4.094428,"eighty":-2.439596,"marketCap":97940295},{"date":"2025-02-21","current":-1.989856,"twenty":-7.587434,"median":-4.067288,"eighty":-2.425077,"marketCap":94022683},{"date":"2025-02-28","current":-1.658213,"twenty":-7.581118,"median":-4.015533,"eighty":-2.382398,"marketCap":78352236},{"date":"2025-03-07","current":-1.768761,"twenty":-7.557146,"median":-4.008177,"eighty":-2.375305,"marketCap":83575718},{"date":"2025-03-14","current":-1.492392,"twenty":-7.521714,"median":-3.98358,"eighty":-2.317741,"marketCap":70517012},{"date":"2025-03-21","current":-1.934582,"twenty":-7.492856,"median":-3.97632,"eighty":-2.289092,"marketCap":91410942},{"date":"2025-03-28","current":-1.767993,"twenty":-7.471273,"median":-3.965429,"eighty":-2.275464,"marketCap":92648122},{"date":"2025-04-04","current":-1.415699,"twenty":-7.450913,"median":-3.886332,"eighty":-2.242644,"marketCap":74186872},{"date":"2025-04-11","current":-1.461367,"twenty":-7.43626,"median":-3.869164,"eighty":-2.174933,"marketCap":76579997},{"date":"2025-04-17","current":-1.50051,"twenty":-7.43626,"median":-3.856489,"eighty":-2.116128,"marketCap":78631247},{"date":"2025-04-21","current":-1.604894,"twenty":-7.43626,"median":-3.851042,"eighty":-2.098794,"marketCap":84101247}],"updateTime":1745332117978}}}